August 19, 2019 at 7:00 AM EDT From Fulcrum press release. PDF Version CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving… Read More »
Fulcrum Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD
The disappearing bomb
How DUX4 could cause FSHD without actually being there BY AMANDA HILL, HIGHLANDS RANCH, COLORADO In the FSHD research field, there is an emerging idea that the damage caused by… Read More »
A new way to detect DUX4
by Gholamhossein Amini Chermahini, MD, Columbus, Ohio Editor’s Note: Dr. Amini Chermahini and his colleagues were awarded the Best Poster Prize at this year’s FSHD International Research Congress. Here he… Read More »
Losmapimod clinical trial key information has been posted
UPDATED 8/9/19 Fulcrum Therapeutics has posted on clinicaltrials.gov information about its upcoming clinical trial of losmapimod. The trial is NOT YET RECRUITING volunteers. People can monitor the clinicaltrials.gov site regularly… Read More »
2019 FSHD International Research Congress Highlights
At the 26th annual FSHD International Research Congress (IRC) this June 19-20, held in a 19th-century palace overlooking the harbor of Marseille, the 180 attendees were treated to a spectacular… Read More »